A systematic review of ustekinumab in the treatment of atopic dermatitis.

A systematic review of ustekinumab in the treatment of atopic dermatitis.

J Dermatolog Treat. 2017 Nov 22;:1-11

Authors: Pan Y, Xu L, Qiao J, Fang H

Abstract
Ustekinumab is a human monoclonal IgG1 antibody targeting the p40 subunit shared by IL-12 and IL-23. We reviewed the published literature by searching from PubMed, EMBASE, Web of Science and ClinicalTrial.gov to evaluate the efficacy and safety of ustekinumab in the treatment of AD. Ten studies including eight cases and two RCT, comprising 107 patients, were included in the systematic review. Analysis all studies, a total of 58 patients (54.2%) gained an effective treatment with little adverse events. Ustekinumab is a well-tolerated and safe treatment with no significant difference in effect from placebo in patients with AD. Further larger randomized controlled trials need to be conducted to identify a suitable regimen for AD and provide more evidence for clinical application.

PMID: 29164954 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2ABB3WC